Clinic
Honorhealth
Honorhealth was paid $23.83M by Medicaid between Jan 2018 and Dec 2024, across 338 billing codes. Its largest line is 99285, emergency room visit (most serious) — 19% of everything it billed.
33Billing provider infoHONORHEALTH
SCOTTSDALE, AZ 85260
SCOTTSDALE, AZ 85260
33aNPI1386608859assigned 04/13/2006
33bProvider typeUrgent Care Clinic/Center
28Total paid$23.83M
24GClaims975,826
24DCodes billed338
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in Arizona
Rank by total paid#6 of 81
Median peer was paid$312K
This provider vs. median76×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 151,949 | $3.41M | |
| 2019 | 150,221 | $3.21M | |
| 2020 | 128,813 | $3.15M | |
| 2021 | 145,543 | $3.40M | |
| 2022 | 143,209 | $3.47M | |
| 2023 | 146,020 | $3.94M | |
| 2024incomplete | 110,071 | $3.25M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 13,862 | 12,485 | $4.43M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 16,081 | 14,981 | $3.07M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.0% | 14,114 | 12,971 | $2.16M |
| G0378 | Hospital observation service, per hour | 7.6% | 24,866 | 8,996 | $1.80M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.0% | 5,978 | 5,498 | $1.43M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.7% | 20,226 | 6,463 | $1.36M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.4% | 17,853 | 11,834 | $1.28M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.2% | 9,978 | 9,309 | $1.24M |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.9% | 1,769 | 1,611 | $703K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.3% | 1,167 | 1,092 | $536K |
| 80053 | Comprehensive metabolic panel | 2.2% | 30,584 | 20,378 | $513K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 2.1% | 733 | 682 | $501K |
326 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.8% | 1,686 | $419K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 5,404 | $385K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 1,859 | $385K |
| 59025 | Fetal non-stress test | 1.5% | 6,367 | $349K |
| 58571 | 1.3% | 86 | $311K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.3% | 6,568 | $300K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.1% | 13,760 | $271K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 3,353 | $210K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,175 | $170K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,135 | $145K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,851 | $129K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 112 | $115K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,782 | $91K |
| 88185 | <1% | 106 | $77K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,456 | $69K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,632 | $68K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,134 | $65K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 524 | $53K |
| 97161 | <1% | 3,722 | $52K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 4,052 | $51K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 884 | $49K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,920 | $49K |
| 93798 | <1% | 525 | $44K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,513 | $43K |
| 96376 | <1% | 11,257 | $43K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,111 | $38K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 27 | $37K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,368 | $37K |
| 74174 | <1% | 38 | $34K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 230 | $32K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 124 | $29K |
| 88341 | <1% | 2,069 | $28K | |
| 70498 | <1% | 58 | $27K | |
| 88307 | <1% | 3,161 | $27K | |
| 57288 | <1% | 45 | $25K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,078 | $25K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 259 | $25K |
| 76801 | <1% | 199 | $25K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 694 | $25K |
| 94060 | <1% | 86 | $23K | |
| C1776 | Joint device (implantable) | <1% | 27 | $22K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 83 | $22K |
| 93976 | <1% | 228 | $22K | |
| 86235 | <1% | 281 | $21K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16,364 | $16K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15,617 | $12K |
| 76830 | Ultrasound, transvaginal | <1% | 251 | $11K |
| 80074 | <1% | 280 | $11K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,814 | $11K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 49,087 | $10K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 24,460 | $10K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 650 | $9K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,952 | $9K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 942 | $9K |
| 93971 | <1% | 835 | $9K | |
| 97165 | <1% | 633 | $9K | |
| 87481 | <1% | 52 | $8K | |
| 87799 | <1% | 245 | $8K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 113 | $7K |
| 83001 | <1% | 160 | $6K | |
| 71045 | Radiologic examination, chest; single view | <1% | 12,148 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,686 | $6K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 14 | $6K |
| 86850 | <1% | 4,355 | $5K | |
| C1771 | Repair device, urinary, incontinence, with sling graft | <1% | 44 | $5K |
| 93970 | <1% | 213 | $4K | |
| 70496 | <1% | 42 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,126 | $4K |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 148 | $4K |
| 36430 | <1% | 60 | $4K | |
| 85610 | <1% | 11,027 | $4K | |
| 84484 | <1% | 13,823 | $4K | |
| 84703 | <1% | 4,975 | $3K | |
| 97162 | <1% | 94 | $3K | |
| 84403 | <1% | 394 | $3K | |
| 87480 | <1% | 326 | $3K | |
| 87186 | <1% | 2,249 | $3K | |
| 80306 | <1% | 4,167 | $3K | |
| C1729 | Catheter, drainage | <1% | 611 | $3K |
| 86635 | <1% | 890 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,672 | $3K |
| 82746 | <1% | 614 | $3K | |
| 97116 | <1% | 2,022 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 209 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 160 | $3K |
| 84702 | <1% | 1,306 | $3K | |
| 86038 | <1% | 1,039 | $3K | |
| 86160 | <1% | 48 | $2K | |
| 36591 | <1% | 1,855 | $2K | |
| 80061 | Lipid panel | <1% | 1,717 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 15,645 | $2K |
| 87040 | <1% | 5,066 | $2K | |
| 85027 | <1% | 11,895 | $2K | |
| 86003 | <1% | 21 | $2K | |
| 81025 | <1% | 8,023 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 10,759 | $2K |
| 84480 | <1% | 80 | $2K | |
| 71250 | <1% | 17 | $2K | |
| 83690 | <1% | 10,845 | $2K | |
| 83880 | <1% | 2,812 | $2K | |
| 81001 | <1% | 20,481 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,506 | $2K |
| 93797 | <1% | 108 | $2K | |
| 82248 | <1% | 8,038 | $1K | |
| 86200 | <1% | 378 | $1K | |
| 0450 | Emergency room services | <1% | 31 | $1K |
| 87070 | <1% | 1,159 | $1K | |
| 84144 | <1% | 77 | $1K | |
| 83735 | <1% | 19,185 | $1K | |
| 87522 | Neg quan hep c or qual rna | <1% | 45 | $1K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,064 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,049 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,570 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 26,796 | $1K |
| 86592 | <1% | 554 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 475 | $1K |
| 85730 | <1% | 4,037 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,032 | $972.34 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 43 | $965.99 |
| 85379 | <1% | 2,895 | $838.55 | |
| 96367 | <1% | 2,162 | $790.86 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,577 | $749.83 |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 26 | $712.30 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,379 | $707.33 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,906 | $704.34 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 663 | $703.84 |
| 84550 | <1% | 1,164 | $698.15 | |
| 83605 | <1% | 4,137 | $656.46 | |
| 82150 | <1% | 121 | $627.93 | |
| 82670 | <1% | 164 | $602.95 | |
| 82962 | <1% | 22,726 | $577.90 | |
| 86900 | <1% | 5,063 | $575.03 | |
| 86706 | <1% | 97 | $552.87 | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 25 | $534.07 |
| 83970 | <1% | 31 | $527.10 | |
| 82731 | <1% | 12 | $503.45 | |
| 0352U | <1% | 40 | $482.60 | |
| 84112 | <1% | 477 | $477.69 | |
| 82550 | <1% | 2,438 | $461.20 | |
| 80320 | <1% | 4,253 | $456.70 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,777 | $449.61 |
| 74018 | <1% | 690 | $448.89 | |
| 84153 | <1% | 55 | $443.33 | |
| 80076 | <1% | 1,312 | $406.98 | |
| 83002 | <1% | 115 | $402.68 | |
| 83615 | <1% | 1,408 | $384.65 | |
| 82330 | <1% | 3,027 | $384.50 | |
| 86376 | <1% | 102 | $375.48 | |
| 80051 | <1% | 2,806 | $370.21 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 487 | $350.11 |
| 84156 | <1% | 518 | $315.41 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,291 | $303.89 |
| 87631 | <1% | 163 | $299.57 | |
| 94726 | <1% | 102 | $298.98 | |
| 80047 | <1% | 1,330 | $288.92 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 6,015 | $286.23 |
| 87077 | <1% | 2,987 | $279.01 | |
| 83516 | <1% | 150 | $277.91 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,345 | $277.53 |
| 88184 | <1% | 190 | $276.95 | |
| 73630 | <1% | 413 | $276.84 | |
| 87510 | <1% | 325 | $276.08 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 11,927 | $271.50 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,362 | $245.03 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,252 | $236.20 |
| 84146 | <1% | 65 | $228.46 | |
| 73030 | <1% | 266 | $224.23 | |
| 73562 | <1% | 440 | $213.05 | |
| 86140 | <1% | 1,956 | $199.89 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 17,437 | $194.41 |
| 84100 | <1% | 7,004 | $194.21 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 100 | $194.20 |
| 80329 | <1% | 2,845 | $194.04 | |
| 82947 | <1% | 3,227 | $186.04 | |
| 87081 | <1% | 452 | $184.18 | |
| 86901 | <1% | 5,140 | $179.35 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 466 | $178.91 |
| 82533 | <1% | 18 | $178.41 | |
| 82784 | <1% | 419 | $178.01 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,054 | $169.54 |
| 84520 | <1% | 2,845 | $165.85 | |
| 88342 | <1% | 2,786 | $149.64 | |
| 82803 | <1% | 58 | $145.75 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 4,254 | $142.63 |
| 84132 | <1% | 2,294 | $141.57 | |
| 86803 | <1% | 294 | $139.71 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 12 | $137.12 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 345 | $135.66 |
| J2704 | Injection, propofol, 10 mg | <1% | 17,104 | $127.45 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,342 | $126.53 |
| 90715 | <1% | 245 | $124.93 | |
| 99152 | <1% | 1,153 | $123.28 | |
| 86039 | <1% | 113 | $121.59 | |
| 87400 | <1% | 1,787 | $118.55 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 38 | $102.62 |
| J3490 | Unclassified drugs | <1% | 2,719 | $102.04 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,463 | $98.88 |
| 82977 | <1% | 16 | $94.07 | |
| 82553 | <1% | 223 | $90.96 | |
| 81003 | <1% | 1,277 | $86.17 | |
| 94760 | <1% | 4,746 | $85.28 | |
| 84436 | <1% | 83 | $84.48 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 11,409 | $79.43 |
| J1815 | Injection, insulin, per 5 units | <1% | 1,286 | $75.84 |
| 85007 | <1% | 2,778 | $74.30 | |
| 82607 | <1% | 246 | $73.92 | |
| 86800 | <1% | 45 | $71.52 | |
| 0011A | <1% | 14 | $69.61 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 9,223 | $68.53 |
| 84165 | <1% | 30 | $65.98 | |
| 88304 | <1% | 786 | $65.41 | |
| 84145 | <1% | 638 | $61.75 | |
| 73610 | <1% | 275 | $59.39 | |
| 85652 | <1% | 1,076 | $58.33 | |
| 88237 | <1% | 15 | $57.67 | |
| 87205 | <1% | 1,553 | $57.56 | |
| 85014 | <1% | 1,904 | $55.28 | |
| 86225 | <1% | 239 | $52.83 | |
| 87210 | <1% | 416 | $49.67 | |
| 82728 | <1% | 185 | $48.21 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 365 | $46.58 |
| 86696 | <1% | 104 | $44.07 | |
| 80050 | General health panel | <1% | 92 | $44.01 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 16 | $43.28 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,162 | $41.88 |
| 83550 | <1% | 248 | $38.03 | |
| 84439 | <1% | 179 | $33.47 | |
| 82672 | <1% | 28 | $29.38 | |
| 72100 | <1% | 44 | $27.80 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,820 | $24.59 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,731 | $22.92 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 460 | $21.31 |
| 82570 | <1% | 604 | $21.24 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 978 | $20.37 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,612 | $18.35 |
| 87147 | <1% | 129 | $17.83 | |
| 85018 | <1% | 309 | $16.39 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 3,759 | $15.57 |
| C1769 | Guide wire | <1% | 2,656 | $14.42 |
| 87660 | <1% | 326 | $14.36 | |
| 83540 | <1% | 267 | $14.30 | |
| 88331 | <1% | 93 | $13.57 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 232 | $13.40 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 59 | $12.74 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 61 | $11.90 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 204 | $11.79 |
| 99153 | Mod sedat endo service >5yrs | <1% | 227 | $10.09 |
| 87807 | <1% | 242 | $8.10 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 286 | $5.56 |
| 87340 | <1% | 230 | $2.85 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,298 | $2.54 |
| A9270 | Non-covered item or service | <1% | 14,881 | $2.05 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 402 | $1.98 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 284 | $1.59 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,519 | $1.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,296 | $0.45 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 561 | $0.24 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 328 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 830 | $0.00 |
| 82565 | 0% | 133 | $0.00 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 1,753 | $0.00 |
| 73080 | 0% | 12 | $0.00 | |
| 88313 | 0% | 287 | $0.00 | |
| 73110 | 0% | 50 | $0.00 | |
| 88112 | 0% | 265 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 212 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 65 | $0.00 |
| 94729 | 0% | 116 | $0.00 | |
| 73130 | 0% | 107 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 307 | $0.00 |
| 88360 | 0% | 85 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 439 | $0.00 |
| 85384 | 0% | 16 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 102 | $0.00 |
| 87497 | 0% | 514 | $0.00 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 14 | $0.00 |
| 80369 | 0% | 18 | $0.00 | |
| 87512 | 0% | 78 | $0.00 | |
| 93017 | 0% | 27 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 49 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 279 | $0.00 |
| Q9956 | Injection, octafluoropropane microspheres, per ml | 0% | 24 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 31 | $0.00 |
| 84295 | 0% | 33 | $0.00 | |
| 84155 | 0% | 27 | $0.00 | |
| 82785 | 0% | 16 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 41 | $0.00 |
| 73590 | 0% | 25 | $0.00 | |
| 76098 | 0% | 13 | $0.00 | |
| 87075 | 0% | 41 | $0.00 | |
| 82172 | 0% | 14 | $0.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 28 | $0.00 |
| 86644 | 0% | 31 | $0.00 | |
| 36592 | 0% | 54 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 19 | $0.00 |
| 80373 | 0% | 18 | $0.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 16 | $0.00 |
| 43264 | 0% | 12 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 965 | $0.00 |
| 36416 | 0% | 2,193 | $0.00 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 18 | $0.00 |
| 74328 | 0% | 14 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 704 | $0.00 |
| 88300 | 0% | 42 | $0.00 | |
| Q9968 | Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg | 0% | 63 | $0.00 |
| 84402 | 0% | 286 | $0.00 | |
| 80197 | 0% | 122 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 869 | $0.00 |
| 88309 | 0% | 15 | $0.00 | |
| 80069 | 0% | 97 | $0.00 | |
| 84154 | 0% | 47 | $0.00 | |
| 87521 | Neg quan hep c or qual rna | 0% | 28 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 53 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 188 | $0.00 |
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg | 0% | 71 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 179 | $0.00 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 41 | $0.00 |
| 86695 | 0% | 104 | $0.00 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 34 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 18 | $0.00 |
| 77001 | 0% | 17 | $0.00 | |
| 80368 | 0% | 18 | $0.00 | |
| 91301 | 0% | 21 | $0.00 | |
| 88311 | 0% | 34 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 49 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHENDRIX, JENIFER (SENIOR NETWORK DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Honorhealth | Phoenix, AZ | $107.15M |
| Honorhealth | Phoenix, AZ | $65.78M |
| Honorhealth | Scottsdale, AZ | $47.05M |
| Honorhealth | Phoenix, AZ | $7.97M |
| Honorhealth | Scottsdale, AZ | $7.44M |
| Honorhealth | Surprise, AZ | $3.33M |
| Honorhealth | Scottsdale, AZ | $232K |
| Honorhealth | Scottsdale, AZ | $13K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.